Timoptic Ocudose Generic Name & Formulations
Timolol (as maleate) 0.25%, 0.5%; (0.2mL/dose); oph soln; preservative-free.
Soln—contact supplier; Ocudose—60; XE—2.5mL, 5mL
Timoptic Ocudose Indications
Elevated intraocular pressure in ocular hypertension or open-angle glaucoma.
Timoptic Ocudose Dosage and Administration
Adults and Children
<2yrs: not established. ≥2yrs: Initially 1 drop of 0.25% twice daily; max 1 drop of 0.5% twice daily. Transfer from other drugs, see full labeling.
Timoptic Ocudose Contraindications
Greater than 1st-degree AV block. Uncompensated cardiac failure. Cardiogenic shock. Sinus bradycardia. History of bronchospasm. Bronchial asthma. Severe COPD.
Timoptic Ocudose Boxed Warnings
Timoptic Ocudose Warnings/Precautions
Not for use as sole agent in angle-closure glaucoma. Poor cardiac reserve should be controlled with digitalis and diuretics. Diabetes. Presbyopia. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Measure intraocular pressure after 4 weeks of treatment. Avoid abrupt cessation. Discontinue at 1st sign of cardiac failure and before surgery. Pregnancy. Nursing mothers: not recommended.
Timoptic Ocudose Pharmacokinetics
Timoptic Ocudose Interactions
May potentiate systemic β-blockers, reserpine, hypoglycemics and mydriatic effect of topical epinephrine. Additive cardiac and pulmonary effects with anticholinesterase miotics. May antagonize bronchodilation from β-adrenergic agonists. May cause conduction defects with calcium channel blockers, digoxin. May be potentiated by CYP2D6 inhibitors (eg, quinidine, SSRIs).
Timoptic Ocudose Adverse Reactions
Ocular irritation, sensitization, rash, dizziness, blurred vision, corneal anesthesia, headache, GI upset, paresthesias. Systemic β-blocker effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure). Aphakic maculopathy (rare).
Timoptic Ocudose Clinical Trials
Timoptic Ocudose Note
Timoptic Ocudose Patient Counseling